Laboratorios Asderco

What Laboratorios Asderco does

Laboratorios Asderco is a privately held pharmaceutical developer founded in 2017 and headquartered at the Parc Cientific de Barcelona, Spain. The company is focused exclusively on dermatology, developing and commercializing treatments for patients suffering from common or rare skin diseases. Its stated operating model is differentiated from traditional pharma: rather than running an internal discovery engine, Asderco concentrates on late-stage assets — products at the end of phase III, pre-registration, or registration — and accelerates their path to market across international geographies.

The company's core technology is dermatological pharmaceutical development applied to late-stage assets. It targets both common dermatological conditions and rare skin diseases, positioning itself as a bridge between de-risked clinical-stage assets and unmet patient need in international markets. The commercial proposition is built around relieving symptoms and curing pathology by shortening the gap between late-stage development and market availability, rather than producing novel molecules from scratch.

Commercially, Asderco operates as a B2B/B2B2C pharmaceutical developer, generating revenue through the sale and licensing of dermatological products in target international markets. Pricing is not publicly disclosed and is governed by regulatory and market access negotiations in each jurisdiction. The company is small — between 1 and 10 employees — with no disclosed funding rounds, named customers, distribution partners, management team, or pipeline assets in the source data, which limits visibility into commercial traction, ownership structure, and execution capacity.

Name

Laboratorios Asderco

Legal name

Laboratorios Asderco

Website

https://asderco.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Laboratorios Asderco is a privately held Barcelona-based pharmaceutical developer focused on dermatology. It acquires late-stage dermatological assets at end of phase III through registration and commercializes them internationally for patients with common or rare skin diseases.

Ownership category

akta.pro rank

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Pharmaceutical product sales: Revenue generated through the commercialization of dermatological pharmaceutical products developed in-house or acquired at late-stage development. Products target common and rare skin diseases for international markets.

Go-to-market motion1 record

Core offering

Laboratorios Asderco develops and commercializes dermatological pharmaceutical products for patients suffering from common or rare skin diseases. The company focuses on late-stage development assets (end of phase III, pre-registration, registration), accelerating them through market access and targeting international markets worldwide.

Product overview

Laboratorios Asderco is a dermatology pharmaceutical company focused on developing and bringing to market novel cutting-edge dermatological products for patients suffering from common or rare skin diseases. The company operates at the late-stage development phase (end of phase III, pre-registration, registration), targeting international markets worldwide. Rather than a traditional software product platform, Asderco functions as a pharmaceutical development company accelerating patient access to dermatological treatments through its development pipeline.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Direct peers

• Almirall: Spanish-headquartered specialty pharmaceutical company with a dermatology-centric portfolio. Highly comparable given shared geography, dermatology focus, and similar mix of branded and generic topical products.
• ISDIN: Spanish dermatology-focused company with a portfolio spanning prescription and dermocosmetic skincare products. Comparable as a Barcelona-adjacent dermatology specialist with similar European base and product mix.

Broad incumbents

• Galderma: One of the largest pure-play dermatology pharmaceutical companies globally, operating across prescription, aesthetics, and consumer skin health. Comparable as a reference point for the dermatology specialty pharmaceutical category Asderco targets.
• LEO Pharma: Danish dermatology-specialty pharmaceutical company with global commercialization across medical dermatology. Comparable as a broader incumbent with a similar specialty-pharma positioning in dermatology.
• Bausch Health (Ortho Dermatologics): Diversified specialty pharma with a substantial prescription dermatology franchise. Comparable as a broad incumbent competing in the same dermatology prescription market Asderco targets.

Emerging players

• Arcutis Biotherapeutics: US-based late-stage dermatology biopharma focused on immuno-dermatology with multiple phase III assets. Comparable as a small, dermatology-only company advancing late-stage development products to market.
• Dermavant Sciences: Late-stage dermatology biopharmaceutical company developing topical therapies for inflammatory skin diseases. Comparable business model — focus on late-stage development and commercialization of dermatology assets.
• Cassiopea: Italian specialty dermatology company developing and commercializing topical prescription products. Comparable as a European-based, dermatology-focused late-stage developer with similar geographic and therapeutic profile.
• Mayne Pharma: Specialty pharmaceutical company with a meaningful dermatology and topical generics franchise. Comparable for the topical/dermatology specialty pharmaceutical positioning, though broader in scope.

Regional players

• Maruho Co., Ltd. Japanese dermatology-focused specialty pharmaceutical company. Comparable as a dermatology pure-play but primarily serves the Japanese market rather than Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/asderco

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Asderco